LM Advisors LLC Invests $1.11 Million in Gilead Sciences, Inc. (NASDAQ:GILD)

LM Advisors LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 12,015 shares of the biopharmaceutical company’s stock, valued at approximately $1,110,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. RFG Advisory LLC raised its position in Gilead Sciences by 4.4% in the 4th quarter. RFG Advisory LLC now owns 13,910 shares of the biopharmaceutical company’s stock worth $1,285,000 after buying an additional 581 shares during the last quarter. Moody Lynn & Lieberson LLC boosted its holdings in shares of Gilead Sciences by 334.0% during the 4th quarter. Moody Lynn & Lieberson LLC now owns 21,307 shares of the biopharmaceutical company’s stock valued at $1,968,000 after acquiring an additional 16,397 shares during the last quarter. First Citizens Bank & Trust Co. grew its stake in shares of Gilead Sciences by 1.3% in the fourth quarter. First Citizens Bank & Trust Co. now owns 15,468 shares of the biopharmaceutical company’s stock worth $1,429,000 after acquiring an additional 193 shares during the period. Finally, Jamison Private Wealth Management Inc. raised its holdings in shares of Gilead Sciences by 5.8% during the fourth quarter. Jamison Private Wealth Management Inc. now owns 27,957 shares of the biopharmaceutical company’s stock valued at $2,582,000 after purchasing an additional 1,521 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on GILD. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Royal Bank of Canada increased their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday, February 12th. BMO Capital Markets raised their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price target for the company. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $107.37 on Monday. The company has a market capitalization of $133.56 billion, a price-to-earnings ratio of 290.19, a PEG ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock’s 50-day simple moving average is $105.27 and its 200-day simple moving average is $100.38. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter last year, the company earned ($1.32) EPS. The firm’s quarterly revenue was down .3% on a year-over-year basis. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.94%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 66.53%.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider now owns 121,152 shares of the company’s stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the sale, the chief financial officer now directly owns 165,674 shares in the company, valued at $16,537,578.68. This trade represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,929 shares of company stock worth $5,644,780. 0.27% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.